2023
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations
Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.Peer-Reviewed Original ResearchConceptsHigher PSA levelsNonmetastatic prostate cancerLocal therapyRadical prostatectomyPSA levelsOverall survivalProstate cancerGood long-term oncological outcomesHigher prostate-specific antigen levelLong-term oncological outcomesProstate-specific antigen levelProstate-specific antigen concentrationCS estimatesInitial local therapyRadical local therapyUnderwent radical prostatectomyEnd Results (SEER) databaseKaplan-Meier methodLong-term outcomesIndependent prognostic valueISUP grade groupCox proportional hazardsImproved CSSPrimary radiotherapyOncological outcomesPersonalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyHormone-sensitive prostate cancerSensitive prostate cancerPositron emission tomographyConventional computerized tomographyDocetaxel chemotherapyClinical trialsProstate cancerCombination of ADTBackbone of treatmentCytoreductive radical prostatectomySequencing of therapyFirst-line treatmentEvaluation of patientsClinical practice guidelinesOngoing clinical trialsAndrogen receptor antagonistPubMed Medline databaseDeprivation therapyInitial managementOverall survivalStaging evaluationBone scanRandomized trialsProstate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstagingMP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT
Rahman S, Syed J, Lokeshwar S, Press B, Monaghan T, Leapman M. MP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT. Journal Of Urology 2022, 207: e680. DOI: 10.1097/ju.0000000000002600.14.Peer-Reviewed Original Research
2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patients
2020
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2019
The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.Peer-Reviewed Original ResearchUpper tract urothelial cancerMedian overall survivalOverall survivalTumor gradeCox proportional hazards regression modelProportional hazards regression modelsNational Cancer DatabaseKaplan-Meier methodHazards regression modelsHigh-grade tumorsGovernment health insuranceDefinitive surgeryDefinitive therapyOlder patientsPatient demographicsMedian ageWorse survivalUrothelial cancerGrade tumorsAlternative therapiesCancer DatabaseOS differenceRadiation therapyPatientsSurvival analysis
2017
Impact of histologic subtype on bladder cancer outcome.
Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.Peer-Reviewed Original ResearchNational Cancer DatabaseVariant histologySmall cell carcinomaSquamous cell carcinomaBladder cancer outcomesCell carcinomaUrothelial carcinomaHazard ratioOverall survivalIndependent predictorsRadical cystectomyCancer outcomesBlack ethnicityBladder cancerMean age 67 yearsU.S. population-based cohortCommon variant histologyNon-urothelial histologyMultivariable Cox regressionSurgical margin statusAge 67 yearsPathologic T stageWorse overall survivalHistory of chemotherapyPopulation-based cohort